Gilead Sciences
GILD
$133.64
+0.56%
Gilead Sciences is a global biopharmaceutical company that develops and commercializes therapies for life-threatening infectious diseases, with a core focus on HIV and viral hepatitis, and a growing presence in oncology through strategic acquisitions. The company is a dominant market leader in antiviral therapeutics and has established itself as a disciplined acquirer, using its substantial cash flow to build a next-generation portfolio in cell therapy and immunology. The current investor narrative is dominated by the company's aggressive acquisition strategy, highlighted by recent multi-billion dollar deals for Tubulis and Arcellx, which are seen as pivotal bets to diversify away from its maturing virology franchise and drive long-term growth in oncology, though this has raised questions about integration risks and near-term capital allocation.…
GILD
Gilead Sciences
$133.64
Related headlines
Investment Opinion: Should I buy GILD Today?
Rating & Thesis: Gilead Sciences is a Hold. The core thesis is that the stock offers a compelling blend of value and income from its cash-generating virology business, but the significant uncertainty and execution risk surrounding its expensive oncology pivot warrant a neutral stance until clearer evidence of successful integration emerges, aligning with the analyst consensus leaning bullish but requiring proof.
Supporting Evidence: The hold rating is supported by four key data points: 1) An undemanding forward P/E of 14.31x, below sector averages, providing a valuation floor. 2) A robust 2.6% dividend yield funded by massive $9.46B annual FCF. 3) Strong underlying profitability with operating margins consistently above 40%. 4) A defensive beta of 0.404, offering portfolio stability. However, modest 4.7% YoY revenue growth tempers near-term excitement.
Risks & Conditions: The two biggest risks are acquisition integration failures and slower-than-expected growth from the oncology pipeline. This Hold would upgrade to a Buy if the forward P/E compressed below 13x on market weakness, or if Q3/Q4 2026 earnings show accelerating revenue from new oncology assets above $1B. It would downgrade to a Sell if quarterly revenue growth decelerates below 2% or if the debt-to-equity ratio climbs sustainably above 1.3. At current levels, the stock is fairly valued relative to its near-term growth profile but undervalued if its long-term oncology strategy succeeds.
Sign up to view all
GILD 12-Month Price Forecast
Gilead is in a transitional phase, fairly valued for its current profile but with embedded optionality on its expensive strategic bets. The neutral stance reflects the high confidence in the stability of the cash-generating business but medium-to-low confidence in the timing and magnitude of the oncology payoff. The stance would upgrade to bullish on evidence of successful commercial execution from the new assets (e.g., oncology revenue surpassing $1.5B quarterly), or downgrade to bearish on signs of capital misallocation or core franchise deterioration. For now, it is a 'show me' story priced for patience.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Gilead Sciences's 12-month outlook, with a consensus price target around $173.73 and implied upside of +30.0% versus the current price.
Average Target
$173.73
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$107 - $174
Analyst target range
Gilead is covered by 16 analysts, indicating substantial institutional interest. The consensus sentiment leans bullish, as evidenced by the recent institutional ratings which are predominantly 'Buy' or 'Overweight' actions from firms like Needham, Truist, UBS, and Wells Fargo in early 2026, with only a couple of 'Sector Perform' ratings noted. The average target price is not explicitly provided in the data, but analyst coverage and recent upgrade actions signal positive bias. The target price range and implied upside cannot be calculated without the specific consensus target price figure. The high target price within the analyst range would likely assume successful integration of recent acquisitions like Arcellx and Tubulis, leading to accelerated growth in oncology, multiple expansion, and pipeline catalysts. Conversely, the low target would factor in risks such as margin compression from increased R&D spend, competitive pressures in HIV, and the potential for acquisition-related synergies to disappoint. The pattern of recent analyst actions shows a series of reiterated Buy ratings following earnings and acquisition announcements, suggesting sustained confidence rather than a wave of new upgrades, which indicates analysts are monitoring execution closely.
Bulls vs Bears: GILD Investment Factors
The evidence currently tilts slightly bullish, anchored by Gilead's formidable financial strength, attractive valuation, and a clear strategic path for growth. The bear case is primarily concerned with execution risk and the patience required for the new strategy to bear fruit. The single most important tension in the investment debate is the trade-off between Gilead's current value as a cash-generating defensive stock and its future value as a growth-oriented oncology leader. The resolution hinges entirely on whether the capital deployed for acquisitions like Arcellx and Tubulis generates returns that justify the premium paid and the integration risks undertaken.
Bullish
- Massive Free Cash Flow Generation: Gilead generated $9.46 billion in trailing twelve-month free cash flow, providing immense financial flexibility. This funds a 2.6% dividend yield, share buybacks, and the aggressive acquisition strategy without straining the balance sheet, which holds $7.56 billion in cash.
- Strong Profitability & High Margins: The company maintains robust profitability with a Q4 2025 gross margin of 86.84% and an operating margin of 40.1%. Net income margins have been stable to expanding, reaching 39.3% in Q3 2025, demonstrating pricing power and operational efficiency.
- Attractive Valuation with Earnings Growth: Gilead trades at a forward P/E of 14.31x, a discount to its trailing P/E of 17.94x, implying expected earnings growth. This valuation is below typical biopharma sector multiples, offering a margin of safety given its cash-generating core business.
- Strategic Oncology Diversification: Recent multi-billion dollar acquisitions (Arcellx, Tubulis) are pivotal bets to build a next-generation oncology and immunology portfolio. This strategy aims to diversify revenue away from the maturing virology franchise and drive long-term growth from 2028 onward.
Bearish
- Aggressive M&A Raises Execution Risk: The recent $7.8B Arcellx and $3.15B Tubulis deals increase integration risks and near-term capital allocation concerns. The success of the long-term oncology pivot is highly dependent on the flawless execution of these expensive acquisitions.
- Mature Core & Modest Revenue Growth: Q4 2025 revenue grew only 4.7% year-over-year to $7.93 billion. The core HIV franchise, while durable, is mature, and newer growth drivers like Cell Therapy ($627M) remain a small portion of total sales.
- Recent Technical Weakness & Lagging Performance: The stock is down 2.58% over the past month, significantly underperforming the S&P 500's 7.36% gain (relative strength -9.94). Trading at 87% of its 52-week range suggests potential overextension and vulnerability to a pullback.
- Debt-Funded Growth Strategy: A debt-to-equity ratio of 1.09 indicates moderate leverage used to finance acquisitions. While manageable given strong cash flow, this increases financial risk if acquired assets fail to deliver expected returns or interest rates rise.
GILD Technical Analysis
Gilead's stock is in a sustained uptrend over the past year, evidenced by a robust 31.66% 1-year price change. The current price of $137.64 positions the stock at approximately 87% of its 52-week range ($93.37 to $157.29), indicating it is trading near its recent highs, which reflects strong investor momentum but also suggests potential overextension relative to its annual low. This positioning near the high end of the range signals market optimism about the company's strategic acquisitions and growth pipeline, but also increases vulnerability to a pullback if execution disappoints. Recent momentum shows a notable divergence, with the stock up 10.19% over the past three months but down 2.58% over the past month, indicating a short-term consolidation or pullback within the longer-term uptrend. This 1-month decline contrasts with the S&P 500's 7.36% gain over the same period, resulting in a stark relative strength reading of -9.94, suggesting Gilead has been a significant laggard recently, likely due to profit-taking or concerns over acquisition costs following its deal-making spree. Key technical support is anchored at the 52-week low of $93.37, while immediate resistance sits near the 52-week high of $157.29. A decisive breakout above $157.29 would signal a resumption of the primary bull trend, whereas a breakdown below the recent consolidation range around $135 could indicate a deeper correction. The stock's beta of 0.404 indicates it is approximately 60% less volatile than the broader market, which is typical for a large-cap pharmaceutical and suggests it offers a defensive characteristic, though recent price swings around acquisition news have shown elevated idiosyncratic volatility.
Beta
0.40
0.40x market volatility
Max Drawdown
-14.7%
Largest decline past year
52-Week Range
$93-$157
Price range past year
Annual Return
+25.6%
Cumulative gain past year
| Period | GILD Return | S&P 500 |
|---|---|---|
| 1m | -3.2% | +8.5% |
| 3m | -1.7% | +2.8% |
| 6m | +10.5% | +4.6% |
| 1y | +25.6% | +32.3% |
| ytd | +9.9% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GILD Fundamental Analysis
Gilead's revenue trajectory is showing modest growth, with Q4 2025 revenue of $7.93 billion representing a 4.7% year-over-year increase. However, examining the quarterly sequence from Q1 2025 ($6.67B) to Q4 2025 ($7.93B) reveals a generally upward trend in absolute sales, though growth rates have been volatile due to product mix and one-time items. Segment data highlights the durability of the HIV franchise, with 'Other HIV' products contributing $5.8 billion, while newer growth drivers like Cell Therapy ($627M) and Trodelvy ($383M) are gaining traction but remain a smaller portion of the total. The company is solidly profitable, reporting Q4 2025 net income of $2.18 billion and a robust gross margin of 86.84%. Profitability has been strong throughout 2025, with net income margins for Q3, Q2, and Q1 at 39.3%, 27.7%, and 19.7%, respectively, indicating generally stable to expanding profitability when excluding the anomalous Q1 2024 loss. The high gross margin is characteristic of the pharmaceutical industry and reflects Gilead's pricing power and efficient manufacturing for its portfolio of small molecule and biologic drugs. The balance sheet and cash flow position is strong, with a debt-to-equity ratio of 1.09 indicating moderate leverage, a current ratio of 1.68 showing ample short-term liquidity, and a trailing twelve-month free cash flow of $9.46 billion. This massive free cash flow generation, which equates to a high single-digit FCF yield on its market cap, provides the company with significant financial flexibility to fund dividends, share repurchases, and its aggressive acquisition strategy without straining its balance sheet, as evidenced by its $7.56 billion cash position at the end of Q4 2025.
Quarterly Revenue
$7.9B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$9.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GILD Overvalued?
Given Gilead's consistent profitability, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 17.94x and a forward PE of 14.31x based on analyst estimates. The discount of the forward PE to the trailing multiple implies the market anticipates earnings growth, aligning with analyst EPS estimates averaging $12.76 for the coming period. Compared to industry averages, Gilead's valuation presents a mixed picture; its trailing PE of 17.94x is likely at a discount to the broader biopharma sector average, which often trades in the low-to-mid 20s, reflecting the market's perception of its mature virology base and the time needed for acquired oncology assets to contribute meaningfully. The price-to-sales ratio of 5.19x and EV/Sales of 6.38x further indicate a valuation that is not demanding relative to its sales base. Historically, Gilead's current trailing PE of 17.94x sits within the middle of its own historical range observed in the provided data, which has fluctuated significantly from negative values during loss-making quarters to over 25x. This mid-range historical positioning suggests the market is neither excessively optimistic nor pessimistic, pricing in a steady outlook that balances its reliable cash-generating legacy business with the growth optionality and execution risk of its new acquisitions.
PE
17.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -5x~982x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Gilead's primary financial risk stems from its aggressive, debt-funded acquisition strategy, with a debt-to-equity ratio of 1.09. While the $9.46B annual FCF provides a cushion, a series of expensive deals increases integration complexity and the risk of overpaying for assets that may not deliver projected synergies. Revenue concentration remains a concern, as the mature HIV franchise ($5.8B in 'Other HIV') must fund the growth pivot while newer oncology assets like Trodelvy ($383M) scale, creating a period of reliance on modest 4-5% top-line growth.
Market & Competitive Risks: The stock trades at a forward P/E of 14.3x, a discount to sector peers, limiting near-term valuation compression risk but reflecting market skepticism about growth. The low beta of 0.404 offers defensive characteristics but may lead to underperformance in strong bull markets, as seen in its recent -9.94% monthly relative strength. Competitive risks are acute in oncology, where Gilead is a challenger, and in HIV, where it must defend its dominant franchise against new entrants and generics. Recent regulatory news on drug tariffs could provide a temporary moat but does not eliminate long-term pricing pressures.
Worst-Case Scenario: The worst-case scenario involves a failure of the acquired oncology assets to gain market share or show clinical efficacy, coupled with unexpected erosion in the HIV franchise due to competition. This would lead to massive asset write-downs, a contraction in the premium multiple paid for acquisitions, and a halt in dividend growth. The realistic downside could see the stock re-test its 52-week low of $93.37, representing a potential loss of approximately -32% from the current price of $137.64. A more probable severe correction could target the $115-$120 range, a -12% to -16% decline, based on technical support levels and a re-rating to a lower earnings multiple.
FAQ
The key risks are, in order of severity: 1) Execution & Integration Risk: The multi-billion dollar acquisitions of Arcellx and Tubulis carry high integration and clinical success risk. 2) Growth Stagnation: Core revenue growth is modest at 4.7% YoY, and the oncology pivot may take years to materially contribute. 3) Financial Leverage: A debt-to-equity ratio of 1.09, while manageable, increases risk if interest rates rise or acquired assets underperform. 4) Competitive & Regulatory: Persistent pricing pressure and competition in both HIV and the crowded oncology field could erode margins and market share.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $140 and $157, driven by steady execution and earnings growth, potentially testing its 52-week high. The Bull Case (25% probability) targets $157 to $170 on successful pipeline catalysts and multiple expansion. The Bear Case (15% probability) warns of a drop to $93-$120 on integration failures or growth disappointments. The most likely outcome is the Base Case, assuming the company successfully manages its transition without major setbacks, leading to a mid-single-digit total return including the dividend.
GILD appears fairly valued to slightly undervalued based on its near-term fundamentals. Its forward P/E of 14.31x is a discount to the broader biopharma sector, which often trades in the low-to-mid 20s. The price-to-sales ratio of 5.19x is also not demanding. This discount reflects the market's skepticism about the growth potential of its mature virology base and the time needed for oncology acquisitions to contribute. The valuation implies the market is paying for steady cash flow and a dividend, not for high growth, offering a margin of safety if the growth bets fail.
GILD is a good buy for investors seeking a defensive, income-generating stock with a reasonable valuation and optionality on future growth, but it is not a high-conviction growth buy. With a 2.6% dividend yield, a forward P/E of 14.3x, and strong free cash flow, it offers a solid foundation. However, the aggressive acquisition strategy introduces significant execution risk. It is a good buy for patient, long-term investors comfortable with a 'show me' story, but less suitable for those seeking near-term explosive growth or with low risk tolerance for M&A integration.
GILD is unequivocally suitable for long-term investment, with a suggested minimum holding period of 3-5 years. Its low beta (0.404) and dividend make it a poor candidate for short-term trading, as it typically lacks the volatility for quick gains. The long-term horizon is necessary to allow the company's strategic oncology investments, which are not expected to significantly boost earnings until 2028 and beyond, to mature and validate the acquisition strategy. Investors should be prepared to collect the dividend and wait for the growth narrative to unfold.